- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06044506
Autologous Natural Killer Cell Therapy for Hepatocellular Carcinoma
A Phase I Study of Autologous Natural Killer Cell Therapy for Hepatocellular Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Ardhi Rahman Ahani, MD
- Phone Number: +62 87870171876
- Email: ardhi.ahani@gmail.com
Study Contact Backup
- Name: Firshan Makbul, MD
- Phone Number: +62 81242625535
- Email: makbulfirshan@gmail.com
Study Locations
-
-
Jakarta
-
Jakarta Pusat, Jakarta, Indonesia, 10430
- Recruiting
- Cipto Mangunkusumo General Hospital
-
Contact:
- Ardhi Rahman Ahani, MD
- Phone Number: +62 87870171876
-
Contact:
- Cosphiadi Irawan, MD, PhD
-
Principal Investigator:
- Cosphiadi Irawan, MD, PhD
-
Sub-Investigator:
- Ardhi Rahman Ahani, MD
-
Sub-Investigator:
- Chyntia Olivia Maurine Jasirwan, MD, PhD
-
Sub-Investigator:
- Radiana Dhewayani Antarianto, MD, MBiomed, PhD
-
Sub-Investigator:
- Isabella Kurnia Liem, MD, MBiomed, PhD
-
Sub-Investigator:
- Iqbal Fasha, MBiomed
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients aged 20-60 years old
- Patients with Hepatocellular Carcinoma (HCC) staged as BCLC B and C
- Karnofsky Performance Status (KPS) score ≥ 70
- Expected patient survival of more than three months
- The following parameters are within the normal range:
Platelet count ≥ 80,000/µL White blood cell count ≥ 3000/µL Neutrophil count ≥ 2000 Hemoglobin ≥ 9 mg/dL International Normalized Ratio (INR) 0.8-1.5 Adequate liver function (bilirubin < 2, SGOT and SGPT < 60 U/L) Adequate kidney function (serum creatinine < 1.3, serum urea < 10)
Exclusion Criteria:
- Refusing to participate in the study
- Afflicted by other malignancies, whether non-HCC liver or other malignancies
- Patients are affected by other conditions such as hypertension, severe coronary disease, myelosuppression, respiratory disorders, and acute or chronic infections
- Patients who have previously undergone transplantation and received other stem cell therapies
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Autologous Natural Killer Cell
Dosage Form: Autologous Natural Killer (NK) Cells. These cells will be harvested from the patient's body and infused back into the patient. Dosage: The specific dose quantity will be determined based on the patient's medical condition and response to the treatment. Customized dosages will be calculated for each individual. Frequency: The treatment will be given through an intravenous method. Duration: The length of the treatment will vary depending on how the patient responds and their medical assessment. It may take several weeks to evaluate its effectiveness and potential impacts thoroughly. |
The therapy will be administered intravenously
The CliniMACS Plus device is an automated cell separation tool that uses MACS Technology.
It incorporates a flexible system designed for isolating clinically labeled cells using MicroBeads.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Optimal treatment dosage
Time Frame: Start of infusion of Autologous NK cells (Day 0) until up to 6 months
|
To evaluate the safety of autologous NK cell infusion and discover dose-limiting toxicities (DLT).
This evaluation will determine the recommended dosage for the next trial phase.
|
Start of infusion of Autologous NK cells (Day 0) until up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor Shrinkage
Time Frame: Up to 6 months
|
CT scans will measure tumor size at baseline and specific post-infusion times.
Tumor response will be assessed using mRECIST criteria.
|
Up to 6 months
|
Immunological Responses
Time Frame: Up to 6 months
|
Flow cytometry will evaluate infused NK cells' biomarkers, such as CD45 and CD56, that persist in peripheral blood.
These biomarkers will be evaluated pre- and post-infusion.
|
Up to 6 months
|
Hematology Profile
Time Frame: Start of infusion of Autologous NK cells (Day 0) until up to 6 months
|
Changes of Complete Blood Count (CBC), Differential Blood Count, Coagulation Profile, Mean Alkaline Phosphatase (ALP), Alanine Amino Transferase (ALT), Aspartate Amio Transferase (AST) from baseline at each assessment time point
|
Start of infusion of Autologous NK cells (Day 0) until up to 6 months
|
Progression-free survival
Time Frame: Start of infusion of Autologous NK cells (Day 0) until progressive disease or death, whichever comes first, up to 2 years
|
This metric indicates the period during which a patient's condition shows no signs of progressing or deteriorating subsequent to the administration of autologous natural killer (NK) cell therapy
|
Start of infusion of Autologous NK cells (Day 0) until progressive disease or death, whichever comes first, up to 2 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Cosphiadi Irawan, MD, PhD, Cipto Mangunkusumo Hospital/Faculty of Medicine, Universitas Indonesia
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22080996
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI); Genentech, Inc.RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditionsUnited States, Canada, Puerto Rico
-
Edward KimBristol-Myers Squibb; National Cancer Institute (NCI)TerminatedUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)CompletedStage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular CarcinomaUnited States
Clinical Trials on Autologous Natural Killer Cell Therapy
-
Envita Medical Center, Inc.SuspendedGlioma | Breast Cancer | Pancreatic Cancer | Prostate Cancer | Colon Cancer | Hepatocellular Cancer | Squamous Cell Lung CancerUnited States
-
Wenxiang WangShanghai Houchao Biotechnology Co., LtdUnknownNon-small Cell Lung CancerChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Ependymoma | Recurrent MedulloblastomaUnited States
-
Southwest Hospital, ChinaUnknownHepatocellular CarcinomaChina
-
Minghui ZhangShanghai Public Health Clinical Center; First Hospital of Tsinghua UniversityRecruitingHepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Non-small Cell Lung CancerChina
-
Yonsei UniversityCompletedAdvanced Biliary Tract CancerKorea, Republic of
-
Asan Medical CenterKorea Research Institute of Bioscience & BiotechnologyCompletedAcute Lymphoblastic Leukemia | Acute Myelogenous LeukemiaKorea, Republic of
-
Asan Medical CenterKorea Research Institute of Bioscience & BiotechnologyCompletedLymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Brain and Central Nervous System Tumors | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative NeoplasmsKorea, Republic of
-
Seoul National University HospitalCompleted
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompleted